A Phase 1 interventional study of [14C]Calderasib in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn what happens to calderasib in a healthy person's body over time and how it is cleared from the body.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive single oral dose of calderasib on Day 1.
Drug: [14C]Calderasib
Oral administration
Also known as: MK-1084
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of plasma Calderasib
Bood samples will be collected to determine the AUC0-inf of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of plasma Calderasib
Blood samples will be collected to determine the AUC0-last of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of plasma Calderasib
Blood samples will be collected to determine the AUC0-24 of plasma calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Maximum Concentration (Cmax) of plasma Calderasib
Blood samples will be collected to determine the Cmax of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Concentration at 24 hours postdose (C24) of plasma Calderasib
Blood samples will be collected to determine the C24 of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Time to Reach Maximum Concentration (Tmax) of plasma Calderasib
Blood samples will be collected to determine the Tmax of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Apparent Half Life (t½) of plasma Calderasib
Blood samples will be collected to determine the t1/2 of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Apparent Total Clearance (CL/F) of plasma Calderasib
Blood samples will be collected to determine the CL/F of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Apparent Volume of Distribution during the Terminal Elimination Phase (Vz/F) of plasma Calderasib
Blood samples will be collected to determine the Vz/F of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
AUC0-inf/Total Radioactivity Ratio of plasma Calderasib
Blood samples will be collected to determine the AUC0-inf/Total Radioactivity Ratio of calderasib in plasma.
Time frame: Predose and at designated timepoints up to Day 15
Amount Excreted in the Urine (Aeu) of Calderasib
Urine samples will be collected to determine the Aeu of calderasib
Time frame: Predose and at designated timepoints up to Day 15
Cumulative Aeu of Calderasib
Urine samples will be collected to determine the cumulative Ae of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Percentage Excreted in the Urine (feu) of Calderasib
Urine samples will be collected to determine the feu of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Cumulative feu of Calderasib
Urine samples will be collected to determine the cumulative feu of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Amount Excreted in the Feces (Aef) of Calderasib
Feces samples will be collected to determine the Aef of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Cumulative Aef of Calderasib
Feces samples will be collected to determine the cumulative Aef of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Percentage Excreted in the Feces (fef) of Calderasib
Feces samples will be collected to determine the fef of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Cumulative fef of Calderasib
Feces samples will be collected to determine the cumulative fef of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Metabolites in Plasma of Calderasib
Blood samples will be collected to determine the metabolites of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Metabolites in Urine of Calderasib
Urine samples will be collected to determine the metabolites of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Metabolites in Feces of Calderasib
Feces samples will be collected to determine the metabolites of calderasib.
Time frame: Predose and at designated timepoints up to Day 15
Number of Participants Experiencing an Adverse Event (AE)
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.
Time frame: Up to ~ 28 days
Number of Participants Discontinuing Study Treatment due to an AE
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study treatment. For each arm, the number of participants experiencing an AE will be assessed.
Time frame: Up to ~ 28 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jun 2024 to primary completion in Aug 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calderasib